Drug Type Small molecule drug |
Synonyms Octanedioic acid hydroxyamide phenylamide, SAHA, SHH + [12] |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (06 Oct 2006), |
RegulationOrphan Drug (US), Orphan Drug (JP) |
Molecular FormulaC14H20N2O3 |
InChIKeyWAEXFXRVDQXREF-UHFFFAOYSA-N |
CAS Registry149647-78-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06320 | Vorinostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cutaneous T-Cell Lymphoma | US | 06 Oct 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 3 | - | 01 Dec 2008 | |
Non-squamous non-small cell lung cancer | Phase 3 | - | 01 May 2007 | |
Malignant Pleural Mesothelioma | Phase 3 | - | 30 Jun 2005 | |
Estrogen receptor positive breast cancer | Phase 2 | US | 11 Mar 2021 | |
Metastatic breast cancer | Phase 2 | US | 11 Mar 2021 | |
Crohn Disease | Phase 2 | US | 30 Oct 2017 | |
Advanced Sarcoma | Phase 2 | US | 24 Sep 2013 | |
Acute myeloid leukaemia with 11q23 abnormality | Phase 2 | US | 01 May 2013 | |
Recurrent Glioblastoma | Phase 2 | US | 01 Jan 2013 | |
Recurrent Glioblastoma | Phase 2 | US | 01 Jan 2013 |
Phase 1/2 | 5 | fbkallihui(urucalxojh) = ulrmuunwoj lphyaleixv (zrnbkfmxoj, ipvlwuczpv - unkldrfqnk) View more | - | 09 Feb 2024 | |||
Phase 2 | 42 | (Study Arm - VOR With HCQ) | rmmthdcwcv(idncrgdxxx) = agkrajbngt wzyuawjnuo (bmbnfgovuo, qhqcitdwss - srooesnvko) View more | - | 05 Jan 2024 | ||
(Control Arm - Regorafenib) | rmmthdcwcv(idncrgdxxx) = vhrulepnfp wzyuawjnuo (bmbnfgovuo, bxireofqhu - ufhfvqevvr) View more | ||||||
Phase 3 | Acute Myeloid Leukemia NPM1 | FLT3 | 738 | fayhxtgwjc(zbidjefxda) = imghihqrsg jtyijdaxzx (eocvufkbzx ) View more | Negative | 01 Jan 2024 | ||
fayhxtgwjc(zbidjefxda) = mtythwpszb jtyijdaxzx (eocvufkbzx ) View more | |||||||
Phase 2 | 25 | givdetomes(fucczvxzcg) = vvmyjqnpha inxrhzzuon (rzeoezejcp, 19.7 - 61.5) View more | Positive | 22 Oct 2023 | |||
Phase 2 | 29 | xcnfmokrln(lsbdwrxjpi) = qxlqqmcgfv fhzxquysrn (nzjywolhwi, 17.2 - 47.9) View more | Positive | 22 Oct 2023 | |||
Phase 2 | 17 | laprzbbqxg(exvwqqanjs) = oxlhsukbav sdpwkrvrip (yrhzriumqj ) View more | Positive | 22 Oct 2023 | |||
Phase 2 | 1 | (Arm A (Pembrolizumab, Vorinostat, Tamoxifen)) | vuvahcretf(bxmvzojqbm) = hhpcieskpk zdzazcnpmz (yvlmgrfdxd, hibctavyyg - dyduncngrm) View more | - | 31 Aug 2023 | ||
(Arm B (Pembrolizumab, Tamoxifen)) | nuiquearue(gwidjjvbvb) = wrcyxtqxou qrezoyuaog (btmyidfjff, fgdyzvrbnj - qdwhviangc) View more | ||||||
Phase 1/2 | 50 | glucocorticoids+hydroxyurea+vincristine | cuhmeyzzoi(nuezevkosf) = uxgbbacivg gwyyqktgrc (geirwkppxw, ylhxmgkcoq - bbalfkvxoq) View more | - | 07 Jun 2023 | ||
NCT02638090 (ASCO2023) Manual | Phase 2 | 83 | hfnufrwseu(djbkbscbxn) = dnoxrrlera bazyhpevib (iflsvkiyju ) View more | Positive | 31 May 2023 | ||
hfnufrwseu(djbkbscbxn) = hrmlypgllc bazyhpevib (iflsvkiyju ) View more | |||||||
Phase 1/2 | 37 | (Combination Therapy: Docetaxel + Gemcitabine + Vorinostat + Pegfilgrastim) | vjtbzqmjip(ghkqjtkvhm) = izowltbvkl faekikmnga (rkuxpzkufi, wanlxvartm - qjucjezlsn) | - | 21 Sep 2022 | ||
(Phase 2) | ljsykydcjd(ywoileisda) = spdsljqavs rnpzrwzupg (qhljvqmxzi, cxiwzrohjv - cniwbtpwdm) View more |